List of Acadia Pharmaceuticals patents

Patents where

Current Assignee

Name

Acadia Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10981871 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C	Patent 10981871 was granted and assigned to Acadia Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	10981871	April 20, 2021
‌ US Patent 10981870 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form	Patent 10981870 was granted and assigned to Acadia Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	10981870	April 20, 2021
‌ US Patent 11464768 Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis	Patent 11464768 was granted and assigned to Acadia Pharmaceuticals on October, 2022 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	11464768	October 11, 2022
‌ US Patent 7601740 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 7601740 was granted and assigned to Acadia Pharmaceuticals on October, 2009 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7601740	October 13, 2009
‌ US Patent 10028944 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 10028944 was granted and assigned to Acadia Pharmaceuticals on July, 2018 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	10028944	July 24, 2018
‌ US Patent 7713995 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 7713995 was granted and assigned to Acadia Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7713995	May 11, 2010
‌ US Patent 9566271 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 9566271 was granted and assigned to Acadia Pharmaceuticals on February, 2017 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	9566271	February 14, 2017
‌ US Patent 7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 7659285 was granted and assigned to Acadia Pharmaceuticals on February, 2010 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7659285	February 9, 2010
‌ US Patent 8377959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 8377959 was granted and assigned to Acadia Pharmaceuticals on February, 2013 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	8377959	February 19, 2013
‌ US Patent 8008323 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 8008323 was granted and assigned to Acadia Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	8008323	August 30, 2011
‌ US Patent 10525046 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 10525046 was granted and assigned to Acadia Pharmaceuticals on January, 2020 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	10525046	January 7, 2020
‌ US Patent 9211289 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 9211289 was granted and assigned to Acadia Pharmaceuticals on December, 2015 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	9211289	December 15, 2015
‌ US Patent 7732462 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 7732462 was granted and assigned to Acadia Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7732462	June 8, 2010
‌ US Patent 8227487 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 8227487 was granted and assigned to Acadia Pharmaceuticals on July, 2012 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	8227487	July 24, 2012
‌ US Patent 7994193 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Patent 7994193 was granted and assigned to Acadia Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7994193	August 9, 2011
‌ US Patent 9050343 Combination of pimavanserin and risperidone for the treatment of psychosis	Patent 9050343 was granted and assigned to Acadia Pharmaceuticals on June, 2015 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	9050343	June 9, 2015
‌ US Patent 7491503 Identification of ligands by selective amplification of cells transfected with receptors	Patent 7491503 was granted and assigned to Acadia Pharmaceuticals on February, 2009 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7491503	February 17, 2009
‌ US Patent 7452682 Identification of 5HT2A receptor ligands by selective amplification of cells transfected with receptors	Patent 7452682 was granted and assigned to Acadia Pharmaceuticals on November, 2008 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7452682	November 18, 2008
‌ US Patent 7732615 N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms	Patent 7732615 was granted and assigned to Acadia Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7732615	June 8, 2010
‌ US Patent 10953000 Combination of pimavanserin and cytochrome P450 modulators	Patent 10953000 was granted and assigned to Acadia Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	10953000	March 23, 2021
‌ US Patent 7790899 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms	Patent 7790899 was granted and assigned to Acadia Pharmaceuticals on September, 2010 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7790899	September 7, 2010
‌ US Patent 10517860 Combination of pimavanserin and cytochrome P450 modulators	Patent 10517860 was granted and assigned to Acadia Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	10517860	December 31, 2019
‌ US Patent 7923564 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms	Patent 7923564 was granted and assigned to Acadia Pharmaceuticals on April, 2011 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	7923564	April 12, 2011
‌ US Patent 8236960 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms	Patent 8236960 was granted and assigned to Acadia Pharmaceuticals on August, 2012 by the United States Patent and Trademark Office.		Acadia Pharmaceuticals	United States Patent and Trademark Office	8236960	August 7, 2012
‌ US Patent 11191757 Combination of pimavanserin and cytochrome P450 modulators	Patent 11191757 was granted and assigned to Acadia Pharmaceuticals on December, 2021 by the United States Patent and Trademark Office.	Acadia Pharmaceuticals	Acadia Pharmaceuticals	United States Patent and Trademark Office	11191757	December 7, 2021

Results per page:

77 results

0 selected

77 results

0 selected